Protagonist Therapeutics Inc Stock Nasdaq
Stocks
US74366E1029
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - PTS | - |
|
| Market Cap | 9.39B 0 8.24B 7.74B 7.08B 13.23B 899B 13.33B 93.03B 36.06B 458B 35.25B 34.48B 1,486B | P/E 2026 * |
31.2x | P/E 2027 * | -306x |
|---|---|---|---|---|---|
| Enterprise Value | 8.85B 0 7.77B 7.3B 6.67B 12.47B 848B 12.57B 87.69B 34B 432B 33.23B 32.5B 1,401B | EV / Sales 2026 * |
16.3x | EV / Sales 2027 * | 43.6x |
| Free-Float |
97.68% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protagonist Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 01/12/2008 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 18/04/2022 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 01/12/2008 |
Harold Selick
CHM | Chairman | 71 | 19/03/2014 |
William Waddill
BRD | Director/Board Member | 69 | 01/07/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +4.35% | +4.23% | +30.02% | 47.86B | |
| -0.36% | +0.31% | +44.62% | +33.23% | 44.46B | |
| -1.60% | +4.32% | +10.35% | +90.73% | 41.85B | |
| -1.82% | -2.53% | +331.99% | +547.32% | 41.34B | |
| -0.62% | -0.06% | +10.15% | +46.02% | 30.04B | |
| -0.78% | +1.73% | +26.40% | +156.27% | 17.59B | |
| -4.94% | -8.74% | - | - | 15.6B | |
| -3.55% | +1.95% | +21.97% | +39.13% | 15.69B | |
| +0.05% | +10.20% | -8.34% | - | 13.93B | |
| Average | -1.47% | +2.66% | +55.17% | +134.68% | 29.82B | |
| Weighted average by Cap. | -1.14% | +1.88% | +68.61% | +142.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 542M 0 476M 447M 409M 764M 51.95B 770M 5.37B 2.08B 26.48B 2.04B 1.99B 85.87B | 203M 0 179M 168M 153M 287M 19.49B 289M 2.02B 781M 9.93B 764M 747M 32.21B |
| Net income | 324M 0 284M 267M 244M 456M 31.01B 460M 3.21B 1.24B 15.81B 1.22B 1.19B 51.27B | -32.12M -0 -28.19M -26.5M -24.23M -45.28M -3.08B -45.61M -318M -123M -1.57B -121M -118M -5.09B |
| Net Debt | -538M -0 -472M -444M -406M -759M -51.56B -764M -5.33B -2.07B -26.29B -2.02B -1.98B -85.23B | -511M -0 -449M -422M -386M -720M -48.96B -726M -5.06B -1.96B -24.96B -1.92B -1.88B -80.93B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
